Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003470007 | SCV004191210 | uncertain significance | Schwannomatosis 2 | 2023-10-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004560174 | SCV005047239 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-11-16 | criteria provided, single submitter | clinical testing | The c.1260+5G>C intronic variant results from a G to C substitution 5 nucleotides after coding exon 11 in the LZTR1 gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration may result in the creation or strengthening of a novel splice donor site. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV004784158 | SCV005396346 | uncertain significance | not provided | 2024-05-10 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge; In silico analysis suggests this variant may impact gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown. |